Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study

Article ID	Journal	Published Year	Pages	File Type
6005064	Basal Ganglia	2012	7 Pages	PDF

Abstract

âº Rotigotine is a non-ergoline dopamine agonist with activity across D1-D5 receptors. âº Rotigotine is administered once-daily via a transdermal patch for treatment of PD. âº A 1-year open label extension study of RECOVER, the rotigotine Phase IIIb trial. âº Adverse events were mild or moderate in intensity and resolved by trial end. âº Rotigotine had beneficial effects on motor function and sleep for up to 1Â year.

Keywords

ASR PDSS-2 PDQ-8 NMSS BDI-II UPDRS Dopamine agonist standard deviation Recover Parkinson’s disease Sleep Rotigotine adverse event Motor function Open-label Unified Parkinson’s Disease Rating Scale Non-motor symptoms scale Beck Depression Inventory